The HCPLive Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.
December 10th 2024
A recent study found that loneliness among adults aged 50 – 80 increased from 2018 to 2022 and dropped in 2023 and 2024.
September 12th 2024
September 10th 2024
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Expert Illustrations & Commentaries™: Envisioning Novel Therapeutic Approaches to Managing ANCA-associated Vasculitis
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis
View More
A Multi-Faceted Approach to Preventing Macular Degeneration
To prevent processes that cause macular degeneration, the researchers employed a one-two punch treatment."CD59 prevents the final step of attack that forms the pore. Once a pore forms, the cell can move a lysosome to close it."
AMD: Gene Expression Pathways React Differently to Various Anti-VEGF Drugs
August 10th 2016Baruch Kuppermann, MD, PhD, and colleagues looked at gene expression modifications in retinal Müller cells treated with anti-VEGFs at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California.
Ranibizumab's Impact on Pigment Epithelial Detachment With or Without RPE Tears
August 10th 2016David Eichenbaum, MD, an ophthalmologist from Florida, presented data from the HARBOR study at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California.
The rate of endophthalmitis after more than 90,000 intravitreal injections was found to be approximately 1 in 3000 in a retrospective study of a consecutive series of cases at a multicenter, retina-only practice. Prophylactic use of topical antibiotics was not found to decrease this rate.
Assessing Rates of Noninfectious Vitritis after Intravitreal Injection of Anti-VEGF Agents
Although intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents has become the therapeutic mainstay for diabetic macular edema and neovascular age-related macular degeneration, it poses a risk of noninfectious uveitis or infectious endopthalmitis.
A retrospective chart review study showed that the location of subfoveal fibrovascular scarring in relation to the retinal pigment epithelium correlated with visual outcome in eyes successfully treated with anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
Oral Bisphosphonate Use Poses Risk of Wet Age-Related Macular Degeneration
Regular users of oral bisphosphonates had a higher risk of developing wet age-related macular degeneration than non-users, according to results of a recent Canadian study, and the longer the use, the greater the increased risk.
Patients with neovascular age-related macular degeneration have shown a suboptimal response to ranibizumab over time. Several studies have established that switching from ranibizumab to aflibercept enhanced visual acuity and resulted in anatomic improvement in many of these patients, but the factors determining visual outcomes remained unclear.
The 10 Worst Things Patients Can Say to Physicians
June 17th 2016Most patients are well-meaning and generally nice. But every now and then, you will get one who is a total pain to deal with. Maybe your patient lies to you, gets sarcastic, asks for special “favors,†or generally just pushes your buttons. We’ve all been there.
10 Worst Things Physicians Say to Patients
June 14th 2016Whether delivered intentionally or not, some physician comments are unhelpful at best and low-blows at worst. Saying certain things to patients can actually increase your risk of having a malpractice suit filed against you, making it especially important for you to always be mindful when speaking with patients.
Combination Treatment with Ranibizumab and AKB-9778 Shows Promise in Diabetic Macular Edema
Study results show that patients with diabetic macular edema are more likely to improve with treatment by a combination of ranibizumab and AKB-9778, as compared to treatment with either alone.
Pain Management after Hip Fracture in Older Patients
August 22nd 2011According to a recent systematic review, limited evidence exists to guide clinicians on the best approaches for managing pain in older (> 50 years of age) patients who have suffered a hip fracture. The strongest evidence supports nerve blockade to improve acute pain and to reduce risk for delirium. Data also suggest that preoperative traction does not improve relief from acute pain.